Are drugs other than tocilizumab and corticosteroids used in the treatment of giant cell arteritis (GCA) (temporal arteritis)?

Updated: Sep 03, 2020
  • Author: Mythili Seetharaman, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

The US Food and Drug Administration (FDA) approved tocilizumab, the first drug specifically approved for giant cell arteritis (GCA), in May 2017. It is a humanized monoclonal anti–interleukin-6 receptor antibody. Approval was based on the GiACTA trial,in which tocilizumab was added to standardized prednisone regimens. [149]

Other possible therapeutic drug options include cyclophosphamide, cyclosporine, dapsone, rituximab (anti-CD20 monoclonal antibody), and abatacept (a recombinant fusion protein that modulates CD28-mediated T cell co-stimulation). [22] Generally, none of these agents is routinely recommended.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!